Experimental CAR-T therapy targets tough childhood blood cancers
NCT ID NCT07623681
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new treatment called PA3-17 injection for children and teens aged 3 to 18 with T-cell leukemia or lymphoma that has not responded to standard therapy or has come back. The treatment uses the patient's own immune cells, modified to recognize and attack cancer cells carrying a protein called CD7. The main goals are to find a safe dose and check for side effects, with a small group of 12 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PA3-17 injection (a type of CAR-T cell therapy targeting CD7)
What this could lead to
If it works, this could point toward a new treatment option for children with hard-to-treat T-cell leukemia or lymphoma that has come back after other treatments.
What could go wrong
This is a very early, small Phase 1 trial with only 12 participants, so it is mainly checking safety and dosing. The treatment may not work, and there are risks like severe immune reactions or side effects from the cell therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL LYMPHOBLASTIC LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
PersonGen Anke Cellular Therapeutice Co,Ltd.
Hefei, Anhui, 230088, China
Contact Phone: •••-•••-•••• Email: •••••@•••••